April 16, 2027: FDA sets target date to act on a capsule form of Epidiolex, the only FDA-approved CBD drug

The U.S. Food and Drug Administration has set April 16, 2027, as its target date to act on Jazz Pharmaceuticals' application for a capsule version of Epidiolex, the cannabidiol (CBD) medicine that remains the only CBD drug the agency has approved.

Jazz disclosed the date in its third-quarter 2026 results on Nov. 2. "The PDUFA target action date for our New Drug Application (NDA) for the oral cannabidiol capsule formulation is April 16, 2027," the company said in its earnings release. On the company's earnings call the same day, Chief Commercial Officer Samantha Pearce said: "The FDA has accepted our NDA for a new cannabidiol oral capsule formulation with a PDUFA date of April 16, 2027, which will improve accessibility and compliance for patients, including certain segments of the adult patient population."

A target action date is not an approval. It is the deadline FDA sets for itself under the Prescription Drug User Fee Act (PDUFA) to respond to an application. As The Marijuana Herald noted in its Nov. 3 report, the review "could conclude with approval, a request for additional information or another regulatory action."

What Jazz is asking FDA to approve

Epidiolex is sold today as an oral solution. Jazz first reported submitting the capsule application in its second-quarter 2026 results, released Aug. 3, saying the filing was meant "to broaden utilization of cannabidiol in currently approved indications and increase flexibility for patients."

That wording matters. The capsule application covers the conditions Epidiolex is already approved to treat, not new ones. According to FDA, Epidiolex is approved for seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, and for seizures associated with tuberous sclerosis complex, in patients 1 year of age and older. The Marijuana Herald reported that Epidiolex first won FDA approval in June 2018.

Jazz is also studying CBD for other uses. In its second-quarter release, the company listed new Epidiolex clinical trials: a Phase 3 trial in developmental and epileptic encephalopathy, a Phase 2/3 trial in juvenile myoclonic epilepsy, and a Phase 3b/4 trial in adults with Lennox-Gastaut syndrome. Those trials are separate from the capsule application, and none of them changes what Epidiolex is approved to treat today.

The sales picture

Epidiolex is a large business. Jazz reported combined Epidiolex/Epidyolex net product sales of $295.4 million in the third quarter of 2026, down from $302.6 million in the same quarter of 2025, a drop of about 2%. The company attributed the dip to lower U.S. "gross-to-net deductions" in the 2025 quarter and lower inventory build in the 2026 quarter due to wholesaler buying patterns.

Over the first nine months of 2026, Epidiolex/Epidyolex sales reached $837.3 million, up from $772.0 million a year earlier, or about 8.5%.

Why a drug application matters for CBD law

For most readers, the bigger legal point is not the capsule itself. It is what Epidiolex's approval means for every other CBD product.

FDA says Epidiolex is the only approved drug product that contains CBD. "There are no other FDA-approved drug products that contain CBD," the agency says in its questions-and-answers page on cannabis and CBD.

That approval is also the reason FDA says CBD cannot be sold as a dietary supplement or added to food in interstate commerce. Under the Federal Food, Drug, and Cosmetic Act, a substance that is an active ingredient in an approved drug, or that was the subject of substantial public clinical investigations as a new drug, is excluded from the dietary supplement definition unless it was marketed as a supplement or food first.

FDA has applied that rule to CBD. "Based on available evidence, FDA has concluded that THC and CBD products are excluded from the dietary supplement definition," the agency says. On food, FDA says it has "concluded that it is a prohibited act to introduce or deliver for introduction into interstate commerce any food (including any animal food or feed) to which THC or CBD has been added."

FDA adds that the law lets the agency approve such a substance for use in food by regulation, but says: "To date, no such regulation has been issued for any substance."

In practice, that leaves a split market. A prescription CBD medicine goes through FDA's drug review, with a set decision date. Consumer CBD products such as gummies, drinks and supplements operate outside that approval system and under FDA's stated view that CBD is not a lawful dietary supplement or food additive.

A new capsule approval, if it comes, would not by itself change FDA's position on consumer CBD. It would add another approved form of the same prescription drug.

Hemp dates arrive first

The April target date lands months after major federal changes for hemp products take effect.

According to Vicente LLP's summary of the September stopgap funding law, the ban on hemp products containing cannabinoids that are not capable of being naturally produced by the cannabis plant, such as synthetic cannabinoids, takes effect Nov. 12, 2026. The new total-THC standard and a 0.4-milligram total THC per container limit for final hemp-derived cannabinoid products take effect Dec. 11, 2026.

Those hemp rules come from Congress, through changes to the federal definition of hemp. FDA's drug review of the Epidiolex capsule is a separate process under drug law. The two tracks do not decide each other, but together they show how differently federal law treats cannabis-derived products depending on whether they are sold as approved medicine or as consumer goods.

What happens next

• FDA's PDUFA target action date for the capsule application is April 16, 2027.
• FDA could approve the capsule, ask for more information, or take another action, as The Marijuana Herald noted.
• The capsule application covers Epidiolex's existing approved uses: Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.
• Federal hemp-definition changes take effect Nov. 12 (synthetic cannabinoids) and Dec. 11 (total-THC standard and per-container limit), per Vicente LLP.
• FDA's stated position that CBD cannot be sold as a dietary supplement or added to food in interstate commerce remains in place.

What we don't know yet

• Jazz has not said what dose strengths the capsules would come in, or how pricing would compare with the oral solution.
• Jazz has not said when it would launch the capsules if FDA approves them.
• We found no public FDA statement on the application. The April date comes from Jazz's own disclosures.

Hemp Law Watch will follow FDA's action on the application and any change in the agency's position on CBD in food and supplements.

This article is for general information only and is not legal or medical advice. Patients should talk with a licensed health care provider about any medication, and businesses should consult a qualified attorney about how federal and state rules apply to them.